Core Viewpoint - ATHA Energy Corp. has filed its final short form prospectus with various Canadian securities commissions, indicating progress in its private placement efforts [1] Group 1 - The company has received a receipt from the British Columbia Securities Commission, which acts as the principal regulator for this filing [1] - The prospectus qualifies up to 18,838,752 units that can be issued upon the exercise of 17,126,138 special warrants [1] - This filing is a follow-up to the company's previous announcement made on October 21, 2025, regarding its private placement [1]

Group 1 - ATHA Energy Corp. has filed its annual information form for the fiscal year ended December 31, 2024 [1] - The company has also filed a preliminary short form prospectus with securities commissions in multiple provinces [1] - The prospectus is related to the qualification of up to 18,838,752 units issuable upon the exercise of 17,126,138 special warrants [1]

Core Points - ATHA Energy Corp. is issuing a news release to clarify its disclosure regarding the Angilak Project following a review by the British Columbia Securities Commission (BCSC) [1] - The BCSC review identified deficiencies in the Company's prior technical disclosure, particularly concerning historical mineral resource estimates and the exploration target model [1]

Core Insights - A major new discovery has been made within the Mineralized RIB Corridor (MRC), specifically the RIB North Discovery, located approximately 1.4 km from the nearest drillhole at the RIB East Discovery [1] - The first drillhole at RIB North, RIBN-DD-001, has yielded the most robust mineralized intersection to date within the MRC and is considered one of the most significant intersections within the Angilak Uranium Project [1] - Drillhole RIBN-DD-001 intersected a total of 26.3 meters of composite uranium mineralization, including 1.9 meters of high-grade mineralization, across over 10 zones from 345.55 meters to 460.05 meters [1] - The hole featured 13.6 meters of continuous mineralization from 426.25 meters to 439.85 meters, which included 1.7 meters of high-grade mineralization with a maximum radioactivity of 55,730 counts per second (CPS) [1] - Mineralization was initially encountered directly above the unconformity at 356.7 meters, extending into graphitic basement rock [1]

Core Insights - ATHA has successfully closed a previously announced CAD $11.5 million over-subscribed bought deal [1] - The first two drill holes at the RIB West Discovery have intersected uranium mineralization over a strike length of approximately 340 meters [1] - This marks the third new discovery of uranium mineralization during the 2025 Angilak Exploration Program within the Angikuni Basin [1] - The RIB East Discovery is defined by eight mineralized drill holes, indicating shallow uranium mineralization across 7 million acres [1] - ATHA holds a 10% carried interest in key exploration projects in the Athabasca Basin operated by NexGen Energy Ltd [1]

Core Points - Athira Pharma, Inc. is a clinical-stage biopharmaceutical company focused on therapies for neurodegenerative diseases [1] - A reverse stock split will occur on September 18, 2025, consolidating shares at a ratio of 1-for-10, approved by stockholders [1][2] - The reverse stock split aims to enhance the stock's marketability and potentially attract more investors [1][4] Stock Performance - Currently, ATHA's stock is priced at $0.38, with a slight increase of 0.29% or $0.0011 [3] - The stock has shown volatility, with a low of $0.35 and a high of $0.40 on the current trading day [3] - Over the past year, ATHA's stock has fluctuated between a high of $0.83 and a low of $0.22 [3] Market Capitalization and Trading Volume - Athira Pharma's market capitalization is approximately $15.1 million [4] - The trading volume on the NASDAQ exchange is 586,605 shares [4] - The reverse stock split may reduce the number of shares outstanding, potentially increasing the stock price [4]

Core Viewpoint - Athira Pharma, Inc. will implement a 10-for-1 reverse stock split to comply with Nasdaq's minimum bid price requirement and enhance the marketability and liquidity of its common stock [1][2][3]. Group 1: Reverse Stock Split Details - The reverse stock split will take effect on September 17, 2025, at 5:00 p.m. Eastern Time, with trading on a split-adjusted basis starting on September 18, 2025 [2]. - Every ten shares of Athira's common stock will be combined into one share, reducing the total number of authorized shares from 900 million to 90 million [3]. - The par value per share will remain unchanged at $0.0001, and adjustments will be made to outstanding options and restricted stock units [3]. Group 2: Impact and Purpose - The reverse stock split aims to increase the share price to meet the $1.00 minimum bid price requirement for continued listing on Nasdaq [2]. - The company anticipates that the split will improve the marketability and liquidity of its common stock, potentially attracting a broader range of investors [2][3]. Group 3: Administrative Aspects - Computershare Inc. will act as the exchange agent for the reverse stock split, and registered stockholders will not need to take action to receive post-split shares [4]. - Stockholders holding shares in brokerage accounts will have their positions automatically adjusted to reflect the reverse stock split [4].

Core Points - ATHA Energy Corp. has issued a news release to clarify certain disclosures following a review by the British Columbia Securities Commission [1] - The company has filed an updated technical report regarding its CMB property located in Newfoundland and Labrador, Canada [1] - The technical report is dated July 8, 2025, and is effective as of June 14, 2025, titled "NI 43-101 Technical Report, Central Mineral Belt Property, Newfoundland and Labrador, Canada" prepared by Stefan Kruse, Ph.D. [1]

Core Insights - Athira Pharma, Inc. presented results from its Phase 1 clinical trial of ATH-1105 at the ALS Nexus 2025 conference, focusing on developing treatments for neurodegenerative diseases like ALS [1][3] - ATH-1105 is a novel, orally available small molecule designed to modulate the neurotrophic HGF system, potentially offering new treatment options for ALS [2][3] Group 1: Clinical Trial Results - The Phase 1 trial of ATH-1105 involved 80 healthy volunteers and evaluated the safety, tolerability, and pharmacokinetics of the drug, showing a favorable safety profile and good tolerability [5] - Results indicated dose-proportional pharmacokinetics and CNS penetration, supporting the continued development of ATH-1105 [3][5] Group 2: Company Overview - Athira Pharma is a clinical-stage biopharmaceutical company based in the Seattle area, focused on developing small molecules to restore neuronal health and slow neurodegeneration [6] - The company aims to alter the course of neurological diseases through its pipeline of drug candidates targeting the neurotrophic HGF system [6]

Core Viewpoint - Athira Pharma reported zero revenue for Q2 2025, focusing on cost containment and strategic pipeline refocus, particularly on its lead candidate ATH-1105 for ALS trials [1][5][10] Financial Performance - EPS (GAAP) for Q2 2025 was $(0.18), an improvement of 74.3% from $(0.70) in Q2 2024 [2] - Research and Development Expenses decreased to $3.7 million, down 83.4% from $22.2 million in Q2 2024 [2][5] - General and Administrative Expenses were reduced to $3.6 million, a 38.8% decrease from $5.9 million in Q2 2024 [2][5] - Net Loss for the quarter was $7.0 million, significantly lower than the $26.9 million loss in Q2 2024, marking a 74.0% reduction [2][5] - Cash reserves stood at $29.8 million as of June 30, 2025, down from $51.3 million at the end of 2024 [6] Strategic Focus - Athira Pharma is concentrating its efforts on ATH-1105, a candidate targeting the HGF pathway to address ALS, following the halt of its previous Alzheimer's candidate, fosgonimeton [3][4][9] - The company completed a Phase 1 clinical trial for ATH-1105, demonstrating a favorable safety profile and the ability to cross the blood-brain barrier [7][10] - Management is exploring strategic alternatives, including potential licensing deals or partnerships, to maximize shareholder value [8][10] Operational Outlook - The company has not provided forward financial or trial guidance for the remainder of 2025 or 2026, creating uncertainty for shareholders [11] - The focus on a single program (ATH-1105) necessitates successful clinical development and securing external partnerships to ensure future funding and operational viability [10]